cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.48597/cp42-2kfe
title: Measurement of Inorganics in precipitation at Listvyanka

description: Measurement of Inorganics in precipitation at Listvyanka
DOI: 10.48597/d797-k7h4
title: Measurement of Inorganics in precipitation at Koksijde

description: Measurement of Inorganics in precipitation at Koksijde
DOI: 10.48597/dhq7-y7wa
title: Measurement of Organic_carbon at Illmitz

description: Measurement of Organic_carbon at Illmitz
DOI: 10.48597/duc8-v3vg
title: Measurement of Precipitation_amount_off at Ogasawara

description: Measurement of Precipitation_amount_off at Ogasawara
DOI: 10.48597/e3cc-mc6g
title: Measurement of Precipitation_amount_off at Chongqing-Guanyinqiao

description: Measurement of Precipitation_amount_off at Chongqing-Guanyinqiao
DOI: 10.48597/f2xe-3rtf
title: Measurement of Aerosol_absorption_coefficient at Zugspitze-Schneefernerhaus

description: Measurement of Aerosol_absorption_coefficient at Zugspitze-Schneefernerhaus
DOI: 10.48597/fc79-hre9
title: Measurement of Inorganics in precipitation at Tappi

description: Measurement of Inorganics in precipitation at Tappi
DOI: 10.48597/fz2v-5ymc
title: Measurement of Organic_mass at Payerne

description: Measurement of Organic_mass at Payerne
DOI: 10.48597/g5na-ttu3
title: Measurement of Inorganics in air and particle phase at Troll

description: Measurement of Inorganics in air and particle phase at Troll
DOI: 10.48597/g8ku-qbsb
title: Measurement of PAHs (polycyclic aromatic hydrocarbons) at Birkenes

description: Measurement of PAHs (polycyclic aromatic hydrocarbons) at Birkenes
DOI: 10.48597/guvz-eyb5
title: Measurement of OC/EC at K-puszta

description: Measurement of OC/EC at K-puszta
DOI: 10.48597/gyca-vdhs
title: Measurement of Aerosol_absorption_coefficient at Bösel

description: Measurement of Aerosol_absorption_coefficient at Bösel
DOI: 10.48597/h2pr-wqpu
title: Measurement of Precipitation_amount_off at Metro Manila

description: Measurement of Precipitation_amount_off at Metro Manila
DOI: 10.48597/j9m3-mpky
title: Measurement of Hygroscopic_growth_factor at Ispra

description: Measurement of Hygroscopic_growth_factor at Ispra
DOI: 10.48597/js5h-cd9x
title: Measurement of Precipitation_amount_off at Oki

description: Measurement of Precipitation_amount_off at Oki
DOI: 10.48597/kaze-dea9
title: Measurement of Hygroscopic_growth_factor at Ispra

description: Measurement of Hygroscopic_growth_factor at Ispra
DOI: 10.48597/khcd-46yt
title: Measurement of Inorganics in air and particle phase at Payerne

description: Measurement of Inorganics in air and particle phase at Payerne
DOI: 10.6084/m9.figshare.24603770
title: Additional file 1 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 1: Supplementary Table 1. IGLC1 mRNA expression in CESC and normal tissues.
DOI: 10.48597/m4kf-bypc
title: Measurement of Nitrogen oxides at Revin

description: Measurement of Nitrogen oxides at Revin
DOI: 10.48597/m5bs-ynaf
title: Measurement of Inorganics in precipitation at Koksijde

description: Measurement of Inorganics in precipitation at Koksijde
DOI: 10.48597/m5rz-7fqm
title: Measurement of Sulphur_dioxide at Kosetice (NOAK)

description: Measurement of Sulphur_dioxide at Kosetice (NOAK)
DOI: 10.48597/md2x-hj5h
title: Measurement of Precipitation_amount_off at Yusuhara

description: Measurement of Precipitation_amount_off at Yusuhara
DOI: 10.6084/m9.figshare.24603770.v1
title: Additional file 1 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 1: Supplementary Table 1. IGLC1 mRNA expression in CESC and normal tissues.
DOI: 10.48597/mggc-yagj
title: Measurement of Carbon_monoxide at Puy de Dôme

description: Measurement of Carbon_monoxide at Puy de Dôme
DOI: 10.48597/ndj4-8676
title: Measurement of Precipitation_amount_off at Hoa Binh

description: Measurement of Precipitation_amount_off at Hoa Binh
DOI: 10.48597/nzda-qua2
title: Measurement of Precipitation_amount_off at Hedo

description: Measurement of Precipitation_amount_off at Hedo
DOI: 10.48597/p4bq-jg23
title: Measurement of Inorganics in precipitation at Primorskaya

description: Measurement of Inorganics in precipitation at Primorskaya
DOI: 10.48597/pfj7-eq2c
title: Measurement of Hygroscopic_growth_factor at Puy de Dôme

description: Measurement of Hygroscopic_growth_factor at Puy de Dôme
DOI: 10.48597/ptwr-r2pc
title: Measurement of Precipitation_amount_off at Chongqing-Guanyinqiao

description: Measurement of Precipitation_amount_off at Chongqing-Guanyinqiao
DOI: 10.48597/puaa-ea6e
title: Measurement of Inorganics in precipitation at Hoa Binh

description: Measurement of Inorganics in precipitation at Hoa Binh
DOI: 10.48597/pxe4-7hdx
title: Measurement of Mercury at Yarner Wood

description: Measurement of Mercury at Yarner Wood
DOI: 10.48597/qg4q-vzqk
title: Measurement of Sulphate_total at Listvyanka

description: Measurement of Sulphate_total at Listvyanka
DOI: 10.48597/qwsz-ngmh
title: Measurement of Nitrogen_dioxide at Kosetice (NOAK)

description: Measurement of Nitrogen_dioxide at Kosetice (NOAK)
DOI: 10.48597/r7w9-d2nr
title: Measurement of Inorganics in air and particle phase at Mt Cimone

description: Measurement of Inorganics in air and particle phase at Mt Cimone
DOI: 10.48597/rb6s-vwfu
title: Measurement of Precipitation_amount_off at Sado-seki

description: Measurement of Precipitation_amount_off at Sado-seki
DOI: 10.48597/rd4r-tpc2
title: Measurement of Mercury at Birkenes

description: Measurement of Mercury at Birkenes
DOI: 10.48597/rnt4-4ubb
title: Measurement of Inorganics in air and particle phase at Banchory

description: Measurement of Inorganics in air and particle phase at Banchory
DOI: 10.48597/rnta-nw7h
title: Measurement of Inorganics in precipitation at Sado-seki

description: Measurement of Inorganics in precipitation at Sado-seki
DOI: 10.6084/m9.figshare.24603773
title: Additional file 2 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 2: Supplementary Table 2. IGLC2 mRNA expression in CESC and normal tissues.
DOI: 10.6084/m9.figshare.24603773.v1
title: Additional file 2 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 2: Supplementary Table 2. IGLC2 mRNA expression in CESC and normal tissues.
DOI: 10.6084/m9.figshare.24603776
title: Additional file 3 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 3: Supplementary Table 3. IGLC3 mRNA expression in CESC and normal tissues.
DOI: 10.6084/m9.figshare.24603776.v1
title: Additional file 3 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 3: Supplementary Table 3. IGLC3 mRNA expression in CESC and normal tissues.
DOI: 10.6084/m9.figshare.24603779
title: Additional file 4 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 4: Supplementary Table 4. IGLC4 mRNA expression in CESC and normal tissues.
DOI: 10.6084/m9.figshare.24603779.v1
title: Additional file 4 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 4: Supplementary Table 4. IGLC4 mRNA expression in CESC and normal tissues.
DOI: 10.6084/m9.figshare.24603782
title: Additional file 5 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 5: Supplementary Table 5. IGLC5 mRNA expression in CESC and normal tissues.
DOI: 10.6084/m9.figshare.24603782.v1
title: Additional file 5 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 5: Supplementary Table 5. IGLC5 mRNA expression in CESC and normal tissues.
DOI: 10.6084/m9.figshare.24603785
title: Additional file 6 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 6: Supplementary Table 6. IGLC6 mRNA expression in CESC and normal tissues.
DOI: 10.6084/m9.figshare.24603785.v1
title: Additional file 6 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 6: Supplementary Table 6. IGLC6 mRNA expression in CESC and normal tissues.
DOI: 10.5281/zenodo.10729545
title: phenacogrammus_urotaenia_spades_01.fasta.gz

description: .
DOI: 10.5281/zenodo.10729546
title: phenacogrammus_urotaenia_spades_01.fasta.gz

description: .
DOI: 10.6084/m9.figshare.24603788
title: Additional file 7 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 7: Supplementary Table 7.  IGLC7 mRNA expression in CESC and normal tissues.
DOI: 10.6084/m9.figshare.24603788.v1
title: Additional file 7 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 7: Supplementary Table 7.  IGLC7 mRNA expression in CESC and normal tissues.
DOI: 10.5281/zenodo.10729461
title: Comparison statistics of VIIRS Version 2 Deep Blue AOD against AERONET observations

description: This data set provides comparison statistics between VIIRS Version 2 Deep Blue AOD and AERONET AOD at 550 nm for each AERONET site over the globe. The comma-separated values (CSV) files contain the site name, latitude, and longitude of each AERONET site, along with the number of matchups, Spearman's rank correlation, median bias, root-mean-square error, fraction within the diagnostic expected error, and fraction within the Global Climate Observing System (GCOS) uncertainty requirement. Separate files are provided for SNPP and NOAA-20 VIIRS data, and for over-land and over-water retrievals. Filenames are descriptive and self-explanatory.
DOI: 10.5281/zenodo.10729462
title: Comparison statistics of VIIRS Version 2 Deep Blue AOD against AERONET observations

description: This data set provides comparison statistics between VIIRS Version 2 Deep Blue AOD and AERONET AOD at 550 nm for each AERONET site over the globe. The comma-separated values (CSV) files contain the site name, latitude, and longitude of each AERONET site, along with the number of matchups, Spearman's rank correlation, median bias, root-mean-square error, fraction within the diagnostic expected error, and fraction within the Global Climate Observing System (GCOS) uncertainty requirement. Separate files are provided for SNPP and NOAA-20 VIIRS data, and for over-land and over-water retrievals. Filenames are descriptive and self-explanatory.
DOI: 10.6084/m9.figshare.24603791
title: Additional file 8 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 8: Supplementary Table 8. IGLC1 mRNA expression in different clinical stages of CESC. Supplementary Table 9. IGLC2 mRNA expression in different clinical stages of CESC. Supplementary Table 10. IGLC3 mRNA expression in different clinical stages of CESC. Supplementary Table 11. IGLC6 mRNA expression in different clinical stages of CESC. Supplementary Table 12. IGLC7 mRNA expression in different clinical stages of CESC. Supplementary Table 13. IGLC1 mRNA expression in different clinical grades of CESC. Supplementary Table 14. IGLC2 mRNA expression in different clinical grades of CESC. Supplementary Table 15. IGLC3 mRNA expression in different clinical grades of CESC. Supplementary Table 16. IGLC6 mRNA expression in different clinical grades of CESC. Supplementary Table 17. IGLC7 mRNA expression in different clinical grades of CESC. Supplementary Table 18. IGLC1 mRNA expression in different ages of CESC patients. Supplementary Table 19. IGLC2 mRNA expression in different ages of CESC patients. Supplementary Table 20. IGLC3 mRNA expression in different ages of CESC patients. Supplementary Table 21. IGLC4 mRNA expression in different ages of CESC patients. Supplementary Table 22. IGLC5 mRNA expression in different ages of CESC patients. Supplementary Table 23. IGLC6 mRNA expression in different ages of CESC patients. Supplementary Table 24. IGLC7 mRNA expression in different ages of CESC patients. Supplementary Table 25. IGLC1 mRNA expression in different T classifications of CESC. Supplementary Table 26. IGLC2 mRNA expression in different T classifications of CESC. Supplementary Table 27. IGLC3 mRNA expression in different T classifications of CESC. Supplementary Table 28. IGLC6 mRNA expression in different T classifications of CESC. Supplementary Table 29. IGLC7 mRNA expression in different T classifications of CESC. Supplementary Table 30. IGLC1 mRNA expression in different N classifications of CESC. Supplementary Table 31. IGLC2 mRNA expression in different N classifications of CESC. Supplementary Table 32. IGLC3 mRNA expression in different N classifications of CESC. Supplementary Table 32. IGLC3 mRNA expression in different N classifications of CESC. Supplementary Table 33. IGLC6 mRNA expression in different N classifications of CESC. Supplementary Table 34. IGLC7 mRNA expression in different N classifications of CESC. Supplementary Table 35. IGLC1 mRNA expression in different M classifications of CESC. Supplementary Table 36. IGLC2 mRNA expression in different M classifications of CESC. Supplementary Table 37. IGLC3 mRNA expression in different M classifications of CESC. Supplementary Table 38. IGLC6 mRNA expression in different M classifications of CESC. Supplementary Table 39. IGLC7 mRNA expression in different M classifications of CESC.
DOI: 10.6084/m9.figshare.24603791.v1
title: Additional file 8 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 8: Supplementary Table 8. IGLC1 mRNA expression in different clinical stages of CESC. Supplementary Table 9. IGLC2 mRNA expression in different clinical stages of CESC. Supplementary Table 10. IGLC3 mRNA expression in different clinical stages of CESC. Supplementary Table 11. IGLC6 mRNA expression in different clinical stages of CESC. Supplementary Table 12. IGLC7 mRNA expression in different clinical stages of CESC. Supplementary Table 13. IGLC1 mRNA expression in different clinical grades of CESC. Supplementary Table 14. IGLC2 mRNA expression in different clinical grades of CESC. Supplementary Table 15. IGLC3 mRNA expression in different clinical grades of CESC. Supplementary Table 16. IGLC6 mRNA expression in different clinical grades of CESC. Supplementary Table 17. IGLC7 mRNA expression in different clinical grades of CESC. Supplementary Table 18. IGLC1 mRNA expression in different ages of CESC patients. Supplementary Table 19. IGLC2 mRNA expression in different ages of CESC patients. Supplementary Table 20. IGLC3 mRNA expression in different ages of CESC patients. Supplementary Table 21. IGLC4 mRNA expression in different ages of CESC patients. Supplementary Table 22. IGLC5 mRNA expression in different ages of CESC patients. Supplementary Table 23. IGLC6 mRNA expression in different ages of CESC patients. Supplementary Table 24. IGLC7 mRNA expression in different ages of CESC patients. Supplementary Table 25. IGLC1 mRNA expression in different T classifications of CESC. Supplementary Table 26. IGLC2 mRNA expression in different T classifications of CESC. Supplementary Table 27. IGLC3 mRNA expression in different T classifications of CESC. Supplementary Table 28. IGLC6 mRNA expression in different T classifications of CESC. Supplementary Table 29. IGLC7 mRNA expression in different T classifications of CESC. Supplementary Table 30. IGLC1 mRNA expression in different N classifications of CESC. Supplementary Table 31. IGLC2 mRNA expression in different N classifications of CESC. Supplementary Table 32. IGLC3 mRNA expression in different N classifications of CESC. Supplementary Table 32. IGLC3 mRNA expression in different N classifications of CESC. Supplementary Table 33. IGLC6 mRNA expression in different N classifications of CESC. Supplementary Table 34. IGLC7 mRNA expression in different N classifications of CESC. Supplementary Table 35. IGLC1 mRNA expression in different M classifications of CESC. Supplementary Table 36. IGLC2 mRNA expression in different M classifications of CESC. Supplementary Table 37. IGLC3 mRNA expression in different M classifications of CESC. Supplementary Table 38. IGLC6 mRNA expression in different M classifications of CESC. Supplementary Table 39. IGLC7 mRNA expression in different M classifications of CESC.
DOI: 10.6084/m9.figshare.24603794
title: Additional file 9 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 9: Supplementary Table 40. OS analysis of patients with CESC. Supplementary Table 41. Kaplan Meier analysis of the correlation between IGLC1 gene expression and OS of patients with CESC. Supplementary Table 42. Kaplan Meier analysis of the correlation between IGLC2 gene expression and OS of patients with CESC. Supplementary Table 43. Kaplan Meier analysis of the correlation between IGLC3 gene expression and OS of patients with CESC. Supplementary Table 44. Kaplan Meier analysis of the correlation between IGLC6 gene expression and OS of patients with CESC. Supplementary Table 45. Kaplan Meier analysis of the correlation between IGLC7 gene expression and OS of patients with CESC. Supplementary Table 46. DSS analysis of patients with CESC. Supplementary Table 47. Kaplan Meier analysis of the correlation between IGLC1 gene expression and Dss of patients with CESC. Supplementary Table 48. Kaplan Meier analysis of the correlation between IGLC2 gene expression and Dss of patients with CESC. Supplementary Table 49. Kaplan Meier analysis of the correlation between IGLC3 gene expression and Dss of patients with CESC. Supplementary Table 50. Kaplan Meier analysis of the correlation between IGLC6 gene expression and Dss of patients with CESC. Supplementary Table 51. Kaplan Meier analysis of the correlation between IGLC7 gene expression and Dss of patients with CESC. Supplementary Table 52. DFI analysis of patients with CESC. Supplementary Table 53. Kaplan Meier analysis of the correlation between IGLC1 gene expression and DFI of patients with CESC. Supplementary Table 54. Kaplan Meier analysis of the correlation between IGLC2 gene expression and DFI of patients with CESC. Supplementary Table 55. Kaplan Meier analysis of the correlation between IGLC3 gene expression and DFI of patients with CESC. Supplementary Table 56. Kaplan Meier analysis of the correlation between IGLC6 gene expression and DFI of patients with CESC. Supplementary Table 57. Kaplan Meier analysis of the correlation between IGLC7 gene expression and DFI of patients with CESC. Supplementary Table 58. PFI analysis of patients with CESC. Supplementary Table 59. Kaplan Meier analysis of the correlation between IGLC1 gene expression and PFI of patients with CESC. Supplementary Table 60. Kaplan Meier analysis of the correlation between IGLC2 gene expression and PFI of patients with CESC. Supplementary Table 61. Kaplan Meier analysis of the correlation between IGLC3 gene expression and PFI of patients with CESC. Supplementary Table 62. Kaplan Meier analysis of the correlation between IGLC6 gene expression and PFI of patients with CESC. Supplementary Table 63. Kaplan Meier analysis of the correlation between IGLC7 gene expression and PFI of patients with CESC.
DOI: 10.6084/m9.figshare.24603794.v1
title: Additional file 9 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 9: Supplementary Table 40. OS analysis of patients with CESC. Supplementary Table 41. Kaplan Meier analysis of the correlation between IGLC1 gene expression and OS of patients with CESC. Supplementary Table 42. Kaplan Meier analysis of the correlation between IGLC2 gene expression and OS of patients with CESC. Supplementary Table 43. Kaplan Meier analysis of the correlation between IGLC3 gene expression and OS of patients with CESC. Supplementary Table 44. Kaplan Meier analysis of the correlation between IGLC6 gene expression and OS of patients with CESC. Supplementary Table 45. Kaplan Meier analysis of the correlation between IGLC7 gene expression and OS of patients with CESC. Supplementary Table 46. DSS analysis of patients with CESC. Supplementary Table 47. Kaplan Meier analysis of the correlation between IGLC1 gene expression and Dss of patients with CESC. Supplementary Table 48. Kaplan Meier analysis of the correlation between IGLC2 gene expression and Dss of patients with CESC. Supplementary Table 49. Kaplan Meier analysis of the correlation between IGLC3 gene expression and Dss of patients with CESC. Supplementary Table 50. Kaplan Meier analysis of the correlation between IGLC6 gene expression and Dss of patients with CESC. Supplementary Table 51. Kaplan Meier analysis of the correlation between IGLC7 gene expression and Dss of patients with CESC. Supplementary Table 52. DFI analysis of patients with CESC. Supplementary Table 53. Kaplan Meier analysis of the correlation between IGLC1 gene expression and DFI of patients with CESC. Supplementary Table 54. Kaplan Meier analysis of the correlation between IGLC2 gene expression and DFI of patients with CESC. Supplementary Table 55. Kaplan Meier analysis of the correlation between IGLC3 gene expression and DFI of patients with CESC. Supplementary Table 56. Kaplan Meier analysis of the correlation between IGLC6 gene expression and DFI of patients with CESC. Supplementary Table 57. Kaplan Meier analysis of the correlation between IGLC7 gene expression and DFI of patients with CESC. Supplementary Table 58. PFI analysis of patients with CESC. Supplementary Table 59. Kaplan Meier analysis of the correlation between IGLC1 gene expression and PFI of patients with CESC. Supplementary Table 60. Kaplan Meier analysis of the correlation between IGLC2 gene expression and PFI of patients with CESC. Supplementary Table 61. Kaplan Meier analysis of the correlation between IGLC3 gene expression and PFI of patients with CESC. Supplementary Table 62. Kaplan Meier analysis of the correlation between IGLC6 gene expression and PFI of patients with CESC. Supplementary Table 63. Kaplan Meier analysis of the correlation between IGLC7 gene expression and PFI of patients with CESC.
DOI: 10.6084/m9.figshare.24603797
title: Additional file 10 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 10: Supplementary Table 64. The pearson correlation coefficients (r) of 5 IGLCs.
DOI: 10.6084/m9.figshare.24603797.v1
title: Additional file 10 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 10: Supplementary Table 64. The pearson correlation coefficients (r) of 5 IGLCs.
DOI: 10.6084/m9.figshare.24603800
title: Additional file 11 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 11: Supplementary Table 65. The correlation analysis between DNAss and IGLC1 expression.
DOI: 10.6084/m9.figshare.24603800.v1
title: Additional file 11 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 11: Supplementary Table 65. The correlation analysis between DNAss and IGLC1 expression.
DOI: 10.6084/m9.figshare.24603803
title: Additional file 12 of Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer

description: Additional file 12: Supplementary Table 66. The correlation analysis between DNAss and IGLC2 expression.